市場調査レポート
商品コード
1065010

体外診断 (IVD) の世界市場 - 2026年までの予測:製品・サービス別 (機器、キット) 、技術別 (イムノアッセイ、MDx、血液検査、尿検査) 、適応別 (糖尿病、腫瘍、心臓病、腎臓病、感染症) 、エンドユーザー別

In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) -Global Forecast -2026

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 415 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=129.43円
体外診断 (IVD) の世界市場 - 2026年までの予測:製品・サービス別 (機器、キット) 、技術別 (イムノアッセイ、MDx、血液検査、尿検査) 、適応別 (糖尿病、腫瘍、心臓病、腎臓病、感染症) 、エンドユーザー別
出版日: 2022年03月09日
発行: MarketsandMarkets
ページ情報: 英文 415 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の体外診断 (IVD) の市場規模は、2021年の982億米ドルから、2026年までに1,131億米ドルに達し、予測期間中のCAGRで2.9%の成長が予測されています。

市場の成長は、主に高齢者人口の増加とそれに伴う慢性疾患や感染症の有病率の増加、先進地域での全自動機器・POC機器の採用拡大、発展途上地域での疾患診断に関する意識の高まり、新しい製品発売に対する業界企業による研究開発投資の増加によってもたらされています。

当レポートでは、世界の体外診断 (IVD) 市場について調査分析し、市場概要、業界動向、セグメント別の市場分析、競合情勢、主要企業などについて、最新の情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 業界考察

  • 業界動向
  • ポーターのファイブフォース分析
  • 規制分析
  • 特許分析
  • 貿易分析
  • エコシステム分析
  • バリューチェーン分析
  • サプライチェーン分析
  • COVID-19の影響分析
  • 価格分析
  • 技術分析
  • 隣接市場分析
  • ケーススタディ

第7章 体外診断 (IVD) 市場:製品・サービス別

  • 試薬・キット
  • 機器
  • データ管理ソフトウェア
  • サービス

第8章 体外診断 (IVD) 市場:技術別

  • イムノアッセイ/免疫化学
  • 臨床化学
  • 分子診断 (MDx)
  • 血液
  • 微生物
  • 凝固・止血
  • 尿検査
  • その他

第9章 体外診断 (IVD) 市場:適応別

  • 感染症
  • 糖尿病
  • 腫瘍
  • 心臓病
  • 薬物検査/薬理ゲノミクス
  • HIV/AIDS
  • 自己免疫疾患
  • 腎臓病
  • その他

第10章 体外診断 (IVD) 市場:エンドユーザー別

  • 病院ラボ
  • 臨床ラボ
  • POC検査センター
  • 患者
  • 学術機関
  • その他

第11章 体外診断 (IVD) 市場:地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他の欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • インドネシア
    • その他のアジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ
  • 中東・アフリカ
    • サウジアラビア
    • その他の中東・アフリカ

第12章 競合情勢

  • 概要
  • 主要企業戦略/成功戦略
  • 市場の主要企業の収益シェア分析
  • 市場シェア分析
  • 主要企業の研究開発評価
  • 主要企業の地理的収益評価
  • 企業の評価象限
  • 競合リーダーシップマッピング
  • 競合ベンチマーキング
  • 競合シナリオ

第13章 企業プロファイル

  • 主要企業
    • ROCHE DIAGNOSTICS
    • DANAHER CORPORATION
    • ABBOTT LABORATORIES, INC.
    • SIEMENS HEALTHINEERS
    • SYSMEX CORPORATION
    • THERMO FISHER SCIENTIFIC, INC.
    • BECTON, DICKINSON AND COMPANY
    • BIOMERIEUX SA
    • BIO-RAD LABORATORIES, INC.
    • JOHNSON & JOHNSON
    • AGILENT TECHNOLOGIES, INC.
    • QIAGEN N.V.
    • QUIDEL CORPORATION
    • DIASORIN S.P.A.
    • ILLUMINA, INC.
  • その他の企業
    • ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
    • PERKINELMER INC.
    • CHEMBIO DIAGNOSTICS, INC.
    • HOLOGIC, INC.
    • SURMODICS, INC.
    • SPEEDX PTY. LTD.
    • GENSPEED BIOTECH GMBH
    • ACCELERATE DIAGNOSTICS, INC.
    • MERCK KGAA
    • CARIS LIFE SCIENCES, INC.

第14章 付録

目次
Product Code: MD 3609

the global IVD market is projected to reach USD 113.1 billion by 2026 from USD 98.2 billion in 2021, at a CAGR of 2.9% during the forecast period. The growth of the IVD market is mainly driven by the rising geriatric population and the subsequent growth in the prevalence of chronic and infectious diseases, increasing adoption of fully automated and POC instruments in developed regions, growing awareness regarding diseases diagnosis in developing regions, and growing R&D investments by industry players to launch new IVD products. Also, the development of disease-specific markers and tests is expected to offer potential growth opportunities to market players in the coming years. However, the unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.

"Reagents & kits segment accounted for the largest share in the IVD market."

Based on product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for the largest share of 68.1% of the IVD market in 2020. Accessibility to a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders in the early stages are expected to drive the growth of this segment.

"Oncology segment is expected to witness the fastest growth in the forecast period."

Based on application, the IVD market is segmented into infectious diseases, diabetes, Oncology, cardiology, drug testing/ pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and other applications. In 2020, infectious diseases accounted for 34.1% of the IVD market. The large share of this segment can be attributed to the rising prevalence of infectious diseases and multi-drug-resistant infectious diseases and the growing need for effective diagnostic tools for these diseases. However, the oncology segment is projected to grow at the highest CAGR of 6.6% during the forecast period. The increasing number of cancer cases across the globe, the growing demand for personalized medicine, and the availability of funding for cancer research are the major factors driving the market growth.

"Immunoassay/immunochemistry account for the largest share in the IVD market."

Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation and hemostasis, urinalysis and other technologies. The immunoassay/immunochemistry segment accounted for 31% of the IVD technologies market in 2020. The growing preference for these technologies in clinical diagnostics over conventional methods and the ability of immunoassay/immunochemistry technologies to offer faster results with high sensitivity and accuracy are contributing to the growth of this market segment.

"Hospital laboratories accounted for the largest share of IVD market in 2020"

Based on the end user, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. In 2020, hospital laboratories accounted for the largest share of 47% of the IVD market, followed by clinical laboratories (23.8%) and POC testing centers (13%). Many diagnostic tests are carried out in hospitals. The acquisition of smaller physician practices and groups by hospitals is becoming a noticeable trend in the US healthcare industry; the continuation of this trend will support the IVD market for hospital laboratories.

"North America accounted for the largest share of the IVD market in 2020"

The IVD market is divided into five major regions-North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 39.8% of the IVD market, followed by Europe (28%), Asia Pacific (22.9%), Latin America (6.5%), and the Middle East & Africa (2.9%). The IVD market in North America is well established, with the US being the major market in this region. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.

A breakdown of the primary participants (supply-side) for the in vitro diagnostics market referred to for this report is provided below:

  • By Company Type: Tier 1-34%, Tier 2-46%, and Tier 3-20%
  • By Designation: C-level-35%, Director Level-25%, and Others-40%
  • By Region: North America-30%, Europe-45%, Asia Pacific-20%, Latin America- 3%, and Middle East and Africa- 2%

Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott (US), and Thermo Fisher Scientific (US) are the leading players in this market. Other players in this market are Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMerieux (France), DiaSorin (Italy), Ortho Clinical Diagnostics (US), and QIAGEN N.V. (Netherlands).

Research Coverage:

The market study covers the in vitro diagnostics market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product and service, by technology, by application, by end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the in vitro diagnostics market and its segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders in understanding the pulse of the market and gaining information on key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION
    • FIGURE 2 IN VITRO DIAGNOSTICS MARKET, BY GEOGRAPHY
  • 1.4 YEARS CONSIDERED FOR THE STUDY
  • 1.5 CURRENCY
    • TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 3 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
    • 2.1.3 PRIMARY SOURCES
    • FIGURE 4 KEY DATA FROM PRIMARY SOURCES
    • FIGURE 5 KEY INDUSTRY INSIGHTS
    • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    • FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 10 REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2020)
    • FIGURE 11 SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2020)
    • FIGURE 13 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE IVD INDUSTRY (2021-2026)
    • FIGURE 14 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET
  • 2.3 DATA TRIANGULATION APPROACH
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2020)
  • 4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 GEOGRAPHIC MIX: IN VITRO DIAGNOSTICS MARKET
  • 4.5 IN VITRO DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 25 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising geriatric population and subsequent growth in the prevalence of chronic and infectious diseases
    • TABLE 3 ESTIMATED INCREASE IN THE GERIATRIC POPULATION, BY REGION (2019-2050)
    • FIGURE 26 CHINA: NUMBER OF PEOPLE WITH DIABETES MELLITUS, 2000-2045 (IN MILLIONS)
      • 5.2.1.2 Shift from centralized to point-of-care testing
      • 5.2.1.3 Growing awareness and initiatives to increase healthcare accessibility in developing countries
      • 5.2.1.4 Changing technological landscape
    • TABLE 4 IN VITRO DIAGNOSTICS MARKET: RECENT PRODUCT LAUNCHES
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Development of disease-specific biomarkers and tests
    • TABLE 5 CANCER BIOMARKERS AND USES IN CLINICAL PRACTICE
      • 5.2.3.2 Growing significance of companion diagnostics
      • 5.2.3.3 Growth opportunities in emerging countries
    • FIGURE 27 ANNUAL PER CAPITA HEALTH EXPENDITURE IN DEVELOPING COUNTRIES, 2019 (USD MILLION)
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape in the EU
    • FIGURE 28 IVDR: KEY AREAS OF IMPACT
      • 5.2.4.2 Operational barriers faced in conducting diagnostic tests

6 INDUSTRY INSIGHTS

  • 6.1 INDUSTRY TRENDS
    • 6.1.1 AUTOMATION OF CLINICAL LABORATORY TECHNIQUES
    • 6.1.2 MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING
    • 6.1.3 GROWING NUMBER OF REAGENT RENTAL AGREEMENTS
  • 6.2 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET
    • 6.2.1 INTENSITY OF COMPETITIVE RIVALRY
    • 6.2.2 BARGAINING POWER OF SUPPLIERS
    • 6.2.3 BARGAINING POWER OF BUYERS
    • 6.2.4 THREAT OF NEW ENTRANTS
    • 6.2.5 THREAT FROM SUBSTITUTES
  • 6.3 REGULATORY ANALYSIS
    • 6.3.1 US
    • TABLE 7 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
    • FIGURE 29 US: REGULATORY PROCESS FOR IVD DEVICES
    • 6.3.2 CANADA
    • FIGURE 30 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
    • 6.3.3 EUROPE
    • TABLE 8 EUROPE: CLASSIFICATION OF IVD DEVICES
    • FIGURE 31 EUROPE: IVDR TIMELINE
    • 6.3.4 JAPAN
    • FIGURE 32 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
    • TABLE 9 JAPAN: CLASSIFICATION OF IVD REAGENTS
    • TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 6.3.5 CHINA
    • TABLE 11 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 6.3.6 INDIA
    • FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
    • 6.3.7 INDONESIA
    • TABLE 12 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
    • 6.3.8 RUSSIA
    • TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES
    • 6.3.9 SAUDI ARABIA
    • TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 6.3.10 MEXICO
    • FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 6.3.11 BRAZIL
    • FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
    • 6.3.12 SOUTH KOREA
    • TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • 6.4 PATENT ANALYSIS
    • FIGURE 36 TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011-DECEMBER 2021)
    • FIGURE 37 PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011-DECEMBER 2021)
  • 6.5 TRADE ANALYSIS
    • 6.5.1 TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS
    • TABLE 17 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2016-2020 (USD MILLION)
    • TABLE 18 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2016-2020 (TONS)
  • 6.6 ECOSYSTEM ANALYSIS
    • FIGURE 38 ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET
  • 6.7 VALUE CHAIN ANALYSIS
    • FIGURE 39 VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET
  • 6.8 SUPPLY CHAIN ANALYSIS
    • FIGURE 40 SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET
  • 6.9 COVID-19 IMPACT ANALYSIS
    • 6.9.1 COVID-19 HEALTH ASSESSMENT
    • 6.9.2 COVID-19 ECONOMIC ASSESSMENT
    • 6.9.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
    • FIGURE 41 CRITERIA IMPACTING THE GLOBAL ECONOMY
    • 6.9.4 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE IN VITRO DIAGNOSTICS MARKET
    • FIGURE 42 COVID-19 IMPACT ON GLOBAL IN VITRO DIAGNOSTICS MARKET
    • FIGURE 43 ROCHE DIAGNOSTICS: IMPACT OF COVID-19
    • FIGURE 44 ABBOTT LABORATORIES, INC.: IMPACT OF COVID-19
  • 6.10 PRICING ANALYSIS
    • TABLE 19 AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS
    • TABLE 20 AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS
    • TABLE 21 AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS
  • 6.11 TECHNOLOGY ANALYSIS
    • 6.11.1 KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET
    • 6.11.2 ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET
  • 6.12 ADJACENT MARKET ANALYSIS
    • FIGURE 45 MICROFLUIDICS MARKET: MARKET OVERVIEW
  • 6.13 CASE STUDY
    • FIGURE 46 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA

7 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 7.1 INTRODUCTION
    • TABLE 22 IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 7.2 REAGENTS & KITS
    • 7.2.1 TECHNOLOGICAL ADVANCES LIKE RAPID DIAGNOSTICS ARE EXPECTED TO BOOST THE GROWTH OF THIS SEGMENT
    • TABLE 23 IVD REAGENTS & KITS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 24 IVD REAGENTS & KITS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
  • 7.3 INSTRUMENTS
    • TABLE 25 IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 26 IVD INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 27 IVD INSTRUMENTS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • 7.3.1 FULLY AUTOMATED INSTRUMENTS
      • 7.3.1.1 Rising incidence of various diseases and the increasing need to process heavy sample load to drive the market growth
    • TABLE 28 FULLY AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 7.3.2 SEMI-AUTOMATED INSTRUMENTS
      • 7.3.2.1 Compact design and cost-effectiveness over automated analyzers are expected to increase the market growth of this segment
    • TABLE 29 SEMI-AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 7.3.3 OTHER INSTRUMENTS
    • TABLE 30 OTHER IVD INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.4 DATA MANAGEMENT SOFTWARE
    • 7.4.1 NEED FOR LABORATORY AUTOMATION DRIVES MARKET GROWTH
    • TABLE 31 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN THE MARKET
    • TABLE 32 IVD DATA MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 33 IVD DATA MANAGEMENT SOFTWARE MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
  • 7.5 SERVICES
    • 7.5.1 GROWING COMPETITIVENESS AND THE INCREASING NEED TO OFFER VALUE-ADDED SERVICES TO BOOST THE MARKET GROWTH
    • TABLE 34 IVD SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 35 IVD SERVICES MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)

8 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 36 IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
  • 8.2 IMMUNOASSAY/IMMUNOCHEMISTRY
    • TABLE 37 IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE IN THE MARKET
    • TABLE 38 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 39 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2026 (USD MILLION)
    • 8.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
    • TABLE 40 ELISA ANALYZERS AVAILABLE IN THE MARKET
    • TABLE 41 ELISA MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 42 ELISA MARKET, BY TYPE, 2019-2026 (USD MILLION)
      • 8.2.1.1 Chemiluminescence immunoassays
        • 8.2.1.1.1 CLIAs hold the largest share of the ELISA market
    • TABLE 43 CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
    • TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
      • 8.2.1.2 Fluorescence immunoassays
        • 8.2.1.2.1 Rapid processing, high sensitivity, and low cost have driven the adoption of FIAs
    • TABLE 45 FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
    • TABLE 46 FLUORESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
      • 8.2.1.3 Colorimetric immunoassays
        • 8.2.1.3.1 Despite widespread use, demand for colorimetric immunoassays has declined due to low sensitivity
    • TABLE 47 COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
    • TABLE 48 COLORIMETRIC IMMUNOASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.2.2 RADIOIMMUNOASSAYS
      • 8.2.2.1 Small sample volumes, rapid processing times offset by high cost and potential health hazards
    • TABLE 49 RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.2.3 RAPID TESTS
      • 8.2.3.1 COVID-19 pandemic drove demand for rapid tests
    • TABLE 50 RAPID TESTS AVAILABLE IN THE MARKET
    • TABLE 51 RAPID TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.2.4 WESTERN BLOTTING
      • 8.2.4.1 Western blotting is the gold standard for result validation
    • TABLE 52 WESTERN BLOTTING SYSTEMS AVAILABLE IN THE MARKET
    • TABLE 53 WESTERN BLOTTING MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS
      • 8.2.5.1 High sensitivity, functionality, and adaptability support the growth of ELISPOT
    • TABLE 54 ELISPOT ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.3 CLINICAL CHEMISTRY
    • TABLE 55 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES
    • TABLE 56 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES
    • TABLE 57 BLOOD GAS ANALYZERS AVAILABLE IN THE MARKET
    • TABLE 58 IVD MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 59 CLINICAL CHEMISTRY MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • 8.3.1 BASIC METABOLIC PANELS
      • 8.3.1.1 Basic metabolic panels hold the largest share of the clinical chemistry market
    • TABLE 60 BASIC METABOLIC PANELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.3.2 LIVER PANELS
      • 8.3.2.1 Growing liver disease burden and alcohol consumption driving market growth
    • TABLE 61 LIVER PANELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.3.3 RENAL PROFILES
      • 8.3.3.1 Rising kidney disease prevalence ensures demand for renal profiles
    • TABLE 62 RENAL PROFILES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.3.4 LIPID PROFILES
      • 8.3.4.1 Growth in CVD caseload supports the adoption of lipid panels
    • TABLE 63 LIPID PROFILES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.3.5 THYROID FUNCTION PANELS
      • 8.3.5.1 Rising awareness and incidence of thyroid diseases drive the market
    • TABLE 64 THYROID FUNCTION PANELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.3.6 ELECTROLYTE PANELS
      • 8.3.6.1 Focus on preventive healthcare to favor the market for electrolyte panels
    • TABLE 65 ELECTROLYTE PANELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.3.7 SPECIALTY CHEMICAL TESTS
      • 8.3.7.1 Includes tests not prescribed regularly, such as protein tests, drugs-of-abuse tests, and therapeutic drug monitoring
    • TABLE 66 SPECIALTY CHEMICAL TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.4 MOLECULAR DIAGNOSTICS
    • TABLE 67 AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN THE MARKET
    • TABLE 68 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 69 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • 8.4.1 POLYMERASE CHAIN REACTION
      • 8.4.1.1 PCR dominates the molecular diagnostics market
    • TABLE 70 PCR INSTRUMENTS AVAILABLE IN THE MARKET
    • TABLE 71 PCR MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
      • 8.4.2.1 Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth
    • TABLE 72 INAAT MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.4.3 HYBRIDIZATION
      • 8.4.3.1 Advanced in hybridization and automation have driven the adoption of hybridization technologies
    • TABLE 73 HYBRIDIZATION MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.4.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
      • 8.4.4.1 Growing use in personalized medicine and declining costs
    • TABLE 74 NGS INSTRUMENTS AVAILABLE IN THE MARKET
    • TABLE 75 DNA SEQUENCING & NGS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.4.5 MICROARRAYS
      • 8.4.5.1 Advantages of microarrays-high throughput, resolution, and sensitivity-drive their adoption
    • TABLE 76 MICROARRAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 8.4.6 OTHER MDX TECHNOLOGIES
    • TABLE 77 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.5 HEMATOLOGY
    • 8.5.1 INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS IS EXPECTED TO DRIVE THE MARKET GROWTH
    • TABLE 78 HEMATOLOGY ANALYZERS AVAILABLE IN THE MARKET
    • TABLE 79 IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.6 MICROBIOLOGY
    • 8.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES WILL BOOST THE GROWTH OF THIS SEGMENT
    • TABLE 80 MICROBIOLOGY INSTRUMENTS AVAILABLE IN THE MARKET
    • TABLE 81 IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.7 COAGULATION & HEMOSTASIS
    • 8.7.1 INCREASING NUMBER OF SURGERIES AND GROWING USE OF ANTICOAGULATION THERAPY WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT
    • TABLE 82 COAGULATION ANALYZERS AVAILABLE IN THE MARKET
    • TABLE 83 POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN THE MARKET
    • TABLE 84 IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.8 URINALYSIS
    • 8.8.1 RISING PREVALENCE OF DIABETES AND KIDNEY DISORDERS WILL HAVE A POSITIVE IMPACT ON THE GROWTH OF THIS SEGMENT
    • TABLE 85 URINALYSIS INSTRUMENTS AVAILABLE IN THE MARKET
    • TABLE 86 IVD MARKET FOR URINALYSIS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.9 OTHER TECHNOLOGIES
    • TABLE 87 BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN THE MARKET
    • TABLE 88 TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN THE MARKET
    • TABLE 89 IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2019-2026 (USD MILLION)

9 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 90 IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 9.2 INFECTIOUS DISEASES
    • 9.2.1 INFECTIOUS DISEASES ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
    • TABLE 91 IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.3 DIABETES
    • 9.3.1 DIABETES PATIENTS REQUIRE CONSTANT MONITORING
    • TABLE 92 GLOBAL DIABETIC PATIENT POPULATION, 2019 VS. 2030 (MILLION)
    • TABLE 93 IVD MARKET FOR DIABETES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.4 ONCOLOGY
    • 9.4.1 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS WILL AID THE EARLY DIAGNOSIS OF CANCER
    • TABLE 94 IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.5 CARDIOLOGY
    • 9.5.1 INCREASING DISEASE BURGEN OF CVD TO DRIVE THE MARKET GROWTH
    • TABLE 95 IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.6 DRUG TESTING/PHARMACOGENOMICS
    • 9.6.1 INCREASING CONSUMPTION OF ILLICIT DRUGS WILL LEAD TO AN INCREASE IN TOXICOLOGY TESTING
    • TABLE 96 IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.7 HIV/AIDS
    • 9.7.1 HIGH PREVALENCE OF AIDS IS EXPECTED TO BOOST THE MARKET GROWTH
    • TABLE 97 IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.8 AUTOIMMUNE DISEASES
    • 9.8.1 DEVELOPMENT OF NOVEL DISEASE-SPECIFIC BIOMARKERS WILL HAVE A POSITIVE IMPACT ON THE MARKET GROWTH
    • TABLE 98 IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.9 NEPHROLOGY
    • 9.9.1 INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASES IS EXPECTED TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT
    • TABLE 99 IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.10 OTHER APPLICATIONS
    • 9.10.1 INCREASING DEMAND FOR SELF-MONITORING KITS IS LIKELY TO HAVE A POSITIVE IMPACT ON THE MARKET GROWTH
    • TABLE 100 IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD MILLION)

10 IN VITRO DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 101 IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.2 HOSPITAL LABORATORIES
    • 10.2.1 GROWING PATIENT POPULATION AND REIMBURSEMENT POLICIES FOR DIAGNOSTIC TESTS WILL DRIVE THE MARKET GROWTH
    • TABLE 102 IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 10.3 CLINICAL LABORATORIES
    • TABLE 103 IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 104 IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY 2019-2026 (USD MILLION)
    • 10.3.1 LARGE/REFERENCE LABORATORIES
      • 10.3.1.1 Rising infectious disease burden and demand for larger testing capacities will drive the growth of this segment
    • TABLE 105 LARGE/REFERENCE LABORATORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 10.3.2 MEDIUM-SIZED LABORATORIES
      • 10.3.2.1 Increasing use of automated instruments to drive market growth
    • TABLE 106 MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 10.3.3 SMALL LABORATORIES
      • 10.3.3.1 Increasing adoption of semi-automated instruments and low-end point-of-care devices will boost segment growth
    • TABLE 107 SMALL LABORATORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 10.4 POINT-OF-CARE TESTING CENTERS
    • 10.4.1 GROWING USE OF POC DEVICES IN HOSPITALS AND CLINICAL LABORATORIES IS EXPECTED TO PROPEL THE GROWTH OF THIS SEGMENT
    • TABLE 108 IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 10.5 PATIENTS
    • 10.5.1 INCREASING ADOPTION OF PATIENT SELF-TESTING KITS TO DRIVE THE MARKET GROWTH
    • TABLE 109 IVD MARKET FOR PATIENTS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 10.6 ACADEMIC INSTITUTES
    • 10.6.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT SUPPORTS MARKET GROWTH
    • TABLE 110 IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 10.7 OTHER END USERS
    • TABLE 111 IVD MARKET FOR OTHER END USERS, BY COUNTRY, 2019-2026 (USD MILLION)

11 IN VITRO DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 112 IVD MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 47 NORTH AMERICA: IVD MARKET SNAPSHOT
    • TABLE 113 NORTH AMERICA: IVD MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 114 NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 115 NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 116 NORTH AMERICA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 117 NORTH AMERICA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 118 NORTH AMERICA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 119 NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 The US dominates the North American Market
    • TABLE 120 US: MACROECONOMIC INDICATORS
    • TABLE 121 US: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 122 US: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 123 US: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 124 US: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 125 US: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 126 US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Increasing prevalence of chronic illness and implementation of favorable government initiatives drive the market in Canada
    • TABLE 127 CANADA: ESTIMATED PREVALENCE OF DIABETES
    • TABLE 128 CANADA: MACROECONOMIC INDICATORS
    • TABLE 129 CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 130 CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 131 CANADA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 132 CANADA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 133 CANADA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 134 CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 135 EUROPE: IVD MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 136 EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 137 EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 138 EUROPE: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 139 EUROPE: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 140 EUROPE: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 141 EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
    • TABLE 142 GERMANY: MACROECONOMIC INDICATORS
    • TABLE 143 GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 144 GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 145 GERMANY: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 146 GERMANY: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 147 GERMANY: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 148 GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.3.2 FRANCE
      • 11.3.2.1 Rising R&D Expenditure in France to drive market growth
    • TABLE 149 FRANCE: MACROECONOMIC INDICATORS
    • TABLE 150 FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 151 FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 152 FRANCE: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 153 FRANCE: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 154 FRANCE: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 155 FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 The increasing number of accredited diagnostic laboratories propels market growth for in vitro diagnostics in the UK
    • TABLE 156 UK: MACROECONOMIC INDICATORS
    • TABLE 157 UK: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 158 UK: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 159 UK: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 160 UK: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 161 UK: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 162 UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
    • TABLE 163 ITALY: MACROECONOMIC INDICATORS
    • TABLE 164 ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 165 ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 166 ITALY: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 167 ITALY: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 168 ITALY: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 169 ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Growth of the geriatric population and rising demand for testing support the market in Spain
    • TABLE 170 SPAIN: MACROECONOMIC INDICATORS
    • TABLE 171 SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 172 SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 173 SPAIN: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 174 SPAIN: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 175 SPAIN: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 176 SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.3.6 RUSSIA
      • 11.3.6.1 Increasing access to quality healthcare will support market growth in Russia
    • TABLE 177 RUSSIA: MACROECONOMIC INDICATORS
    • TABLE 178 RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 179 RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 180 RUSSIA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 181 RUSSIA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 182 RUSSIA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 183 RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 184 ROE: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 185 ROE: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 186 ROE: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 187 ROE: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 188 ROE: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 189 ROE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 48 ASIA PACIFIC: IVD MARKET SNAPSHOT
    • TABLE 190 ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 192 ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 193 ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 194 ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 195 ASIA PACIFIC: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 196 ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.4.1 JAPAN
      • 11.4.1.1 Universal healthcare reimbursement policy to drive market growth in Japan
    • TABLE 197 JAPAN: MACROECONOMIC INDICATORS
    • TABLE 198 JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 199 JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 200 JAPAN: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 201 JAPAN: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 202 JAPAN: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 203 JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.4.2 CHINA
      • 11.4.2.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
    • TABLE 204 CHINA: MACROECONOMIC INDICATORS
    • TABLE 205 CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 206 CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 207 CHINA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 208 CHINA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 209 CHINA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 210 CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Increasing private & public investments in the country's healthcare system will drive market growth
    • TABLE 211 INDIA: MACROECONOMIC INDICATORS
    • TABLE 212 INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 213 INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 214 INDIA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 215 INDIA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 216 INDIA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 217 INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Increased geriatric population coupled with a parallel increase in chronic illnesses to drive the market growth
    • TABLE 218 SOUTH KOREA: MACROECONOMIC INDICATORS
    • TABLE 219 SOUTH KOREA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 220 SOUTH KOREA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 221 SOUTH KOREA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 222 SOUTH KOREA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 223 SOUTH KOREA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 224 SOUTH KOREA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.4.5 INDONESIA
      • 11.4.5.1 Increasing insurance penetration and rising burden of infectious diseases to drive market growth
    • TABLE 225 INDONESIA: MACROECONOMIC INDICATORS
    • TABLE 226 INDONESIA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 227 INDONESIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 228 INDONESIA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 229 INDONESIA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 230 INDONESIA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 231 INDONESIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.4.6 REST OF ASIA PACIFIC
    • TABLE 232 ROAPAC: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 233 ROAPAC: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 234 ROAPAC: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 235 ROAPAC: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 236 ROAPAC: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 237 ROAPAC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
  • 11.5 LATIN AMERICA
    • TABLE 238 LATIN AMERICA: IVD MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 239 LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 240 LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 241 LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 242 LATIN AMERICA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 243 LATIN AMERICA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 244 LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.5.1 BRAZIL
      • 11.5.1.1 Improving healthcare infrastructure in Brazil to drive the growth of the IVD market
    • TABLE 245 BRAZIL: MACROECONOMIC INDICATORS
    • TABLE 246 BRAZIL: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 247 BRAZIL: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 248 BRAZIL: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 249 BRAZIL: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 250 BRAZIL: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 251 BRAZIL: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.5.2 MEXICO
      • 11.5.2.1 Improving accessibility and affordability of healthcare services to drive market growth for in vitro diagnostics
    • TABLE 252 MEXICO: MACROECONOMIC INDICATORS
    • TABLE 253 MEXICO: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 254 MEXICO: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 255 MEXICO: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 256 MEXICO: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 257 MEXICO: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 258 MEXICO: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.5.3 REST OF LATIN AMERICA
    • TABLE 259 ROLA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 260 ROLA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 261 ROLA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 262 ROLA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 263 ROLA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 264 ROLA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • TABLE 265 MIDDLE EAST & AFRICA: IVD MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 266 MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 267 MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 268 MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 269 MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 270 MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 271 MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.6.1 SAUDI ARABIA
      • 11.6.1.1 High incidence of lifestyle diseases coupled with increasing healthcare budget is to drive market growth
    • TABLE 272 SAUDI ARABIA: MACROECONOMIC INDICATORS
    • TABLE 273 SAUDI ARABIA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 274 SAUDI ARABIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 275 SAUDI ARABIA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 276 SAUDI ARABIA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 277 SAUDI ARABIA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 278 SAUDI ARABIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)
    • 11.6.2 REST OF MIDDLE EAST & AFRICA
    • TABLE 279 ROMEA: IVD MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 280 ROMEA: IVD INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 281 ROMEA: IVD MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 282 ROMEA: IVD MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 283 ROMEA: IVD MARKET, BY END USER, 2019-2026 (USD MILLION)
    • TABLE 284 ROMEA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019-2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE IN VITRO DIAGNOSTICS MARKET
  • 12.4 MARKET SHARE ANALYSIS
    • TABLE 285 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION
    • 12.4.1 MARKET SHARE ANALYSIS, BY TECHNOLOGY
      • 12.4.1.1 Clinical chemistry
    • FIGURE 52 CLINICAL CHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
      • 12.4.1.2 Immunochemistry/immunoassay analyzers
    • FIGURE 53 IMMUNOASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
      • 12.4.1.3 Microbiology
    • FIGURE 54 MICROBIOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
      • 12.4.1.4 Molecular diagnostics
    • FIGURE 55 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
      • 12.4.1.5 Hematology
    • FIGURE 56 HEMATOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
      • 12.4.1.6 Coagulation & hemostasis
    • FIGURE 57 COAGULATION & HEMOSTASIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
      • 12.4.1.7 Urinalysis
    • FIGURE 58 URINALYSIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
  • 12.5 R&D ASSESSMENT OF KEY PLAYERS
  • 12.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS
    • FIGURE 59 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC REVENUE MIX
  • 12.7 COMPANY EVALUATION QUADRANT
    • 12.7.1 STARS
    • 12.7.2 PERVASIVE PLAYERS
    • 12.7.3 EMERGING LEADERS
    • 12.7.4 PARTICIPANTS
    • FIGURE 60 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX, 2020
  • 12.8 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS
    • 12.8.1 PROGRESSIVE COMPANIES
    • 12.8.2 DYNAMIC COMPANIES
    • 12.8.3 STARTING BLOCKS
    • 12.8.4 RESPONSIVE COMPANIES
    • FIGURE 61 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UPS
  • 12.9 COMPETITIVE BENCHMARKING
    • TABLE 286 OVERALL COMPANY FOOTPRINT
    • TABLE 287 COMPANY FOOTPRINT: BY PRODUCT AND SERVICE
    • TABLE 288 COMPANY FOOTPRINT: BY TECHNOLOGY
    • TABLE 289 COMPANY FOOTPRINT: BY APPLICATION
    • TABLE 290 COMPANY FOOTPRINT: BY END USER
  • 12.10 COMPETITIVE SCENARIO
    • 12.10.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 291 PRODUCT LAUNCHES & APPROVALS, 2020-2022
    • 12.10.2 DEALS
    • TABLE 292 DEALS, 2021
    • 12.10.3 OTHER DEVELOPMENTS
    • TABLE 293 OTHER DEVELOPMENTS, 2021

13 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 13.1 KEY PLAYERS
    • 13.1.1 ROCHE DIAGNOSTICS
    • TABLE 294 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 62 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2020)
    • TABLE 295 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 296 DEALS
    • 13.1.2 DANAHER CORPORATION
    • TABLE 297 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 63 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
    • TABLE 298 DEALS
    • 13.1.3 ABBOTT LABORATORIES, INC.
    • TABLE 299 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 64 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
    • TABLE 300 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 301 DEALS
    • 13.1.4 SIEMENS HEALTHINEERS
    • TABLE 302 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
    • FIGURE 65 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2021)
    • TABLE 303 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 304 DEALS
    • TABLE 305 OTHER DEVELOPMENTS
    • 13.1.5 SYSMEX CORPORATION
    • TABLE 306 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 66 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
    • TABLE 307 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 308 DEALS
    • TABLE 309 OTHER DEVELOPMENTS
    • 13.1.6 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 310 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 67 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
    • TABLE 311 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 312 DEALS
    • TABLE 313 OTHER DEVELOPMENTS
    • 13.1.7 BECTON, DICKINSON AND COMPANY
    • TABLE 314 BD: BUSINESS OVERVIEW
    • FIGURE 68 BD: COMPANY SNAPSHOT (2021)
    • TABLE 315 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 316 DEALS
    • 13.1.8 BIOMERIEUX SA
    • TABLE 317 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 69 BIOMERIEUX SA: COMPANY SNAPSHOT (2020)
    • TABLE 318 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 319 DEALS
    • 13.1.9 BIO-RAD LABORATORIES, INC.
    • TABLE 320 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 70 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
    • TABLE 321 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 322 DEALS
    • 13.1.10 JOHNSON & JOHNSON
    • TABLE 323 JOHNSON & JOHNSON: BUSINESS OVERVIEW
    • FIGURE 71 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
    • 13.1.11 AGILENT TECHNOLOGIES, INC.
    • TABLE 324 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 72 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
    • TABLE 325 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 326 DEALS
    • 13.1.12 QIAGEN N.V.
    • TABLE 327 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 73 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
    • TABLE 328 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
    • TABLE 329 DEALS
    • TABLE 330 OTHER DEVELOPMENTS
    • 13.1.13 QUIDEL CORPORATION
    • TABLE 331 QUIDEL CORPORATION: BUSINESS OVERVIEW
    • FIGURE 74 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
    • TABLE 332 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 333 DEALS
    • TABLE 334 OTHER DEVELOPMENTS
    • 13.1.14 DIASORIN S.P.A.
    • TABLE 335 DIASORIN S.P.A.: BUSINESS OVERVIEW
    • FIGURE 75 DIASORIN S.P.A.: COMPANY SNAPSHOT (2020)
    • TABLE 336 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 337 DEALS
    • TABLE 338 OTHER DEVELOPMENTS
    • 13.1.15 ILLUMINA, INC.
    • TABLE 339 ILLUMINA, INC.: BUSINESS OVERVIEW
    • FIGURE 76 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
    • TABLE 340 PRODUCT REGISTRATIONS, LAUNCHES, AND APPROVALS
    • TABLE 341 DEALS
    • TABLE 342 OTHER DEVELOPMENTS
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
    • TABLE 343 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
    • FIGURE 77 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2020)
    • 13.2.2 PERKINELMER INC.
    • TABLE 344 PERKINELMER, INC.: BUSINESS OVERVIEW
    • FIGURE 78 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
    • 13.2.3 CHEMBIO DIAGNOSTICS, INC.
    • TABLE 345 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW
    • FIGURE 79 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020)
    • 13.2.4 HOLOGIC, INC.
    • TABLE 346 HOLOGIC, INC.: BUSINESS OVERVIEW
    • FIGURE 80 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
    • 13.2.5 SURMODICS, INC.
    • TABLE 347 SURMODICS, INC.: BUSINESS OVERVIEW
    • FIGURE 81 SURMODICS, INC.: COMPANY SNAPSHOT (2020)
    • 13.2.6 SPEEDX PTY. LTD.
    • 13.2.7 GENSPEED BIOTECH GMBH
    • 13.2.8 ACCELERATE DIAGNOSTICS, INC.
    • 13.2.9 MERCK KGAA
    • 13.2.10 CARIS LIFE SCIENCES, INC.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS